Picard Medical shares surge 27.71% premarket after showcasing Emperor TAH in vitro data and successful in vivo implantation.

Picard Medical surged 27.71% in premarket trading following the presentation of in vitro and in vivo data on its Emperor Total Artificial Heart (TAH) at an international conference. The Emperor TAH demonstrated autoregulation and afterload independence in vitro, eliminated the need for external pneumatic drivers, and confirmed surgical feasibility through its first in vivo implantation. These advancements align with the SynCardia platform’s performance and position the device for chronic animal studies and clinical translation, signaling significant progress in the company’s artificial heart development. The results underscore potential long-term commercial viability and regulatory milestones, driving investor optimism.